Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation

Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation is an extremely rare inherited bleeding disorder caused by a specific point mutation (Met358Arg) in the SERPINA1 gene, which encodes alpha-1-antitrypsin (AAT). This mutation converts AAT from a serine protease inhibitor primarily targeting neutrophil elastase into a potent inhibitor of thrombin, a key enzyme in the blood coagulation cascade. As a result, the mutant AAT protein massively inhibits thrombin activity, leading to a severe hemorrhagic tendency. The condition primarily affects the coagulation system, manifesting as a severe bleeding diathesis. Key clinical features include spontaneous and life-threatening hemorrhages, markedly prolonged coagulation times (particularly the thrombin time and partial thromboplastin time), and bleeding episodes that can be fatal. The disorder was first described in a child who presented with a fatal bleeding disorder. Because the mutant protein functions as an extremely efficient antithrombin, affected individuals experience profoundly impaired clot formation. This condition is exceptionally rare, with very few cases reported in the medical literature. Management is primarily supportive and may include blood product transfusions and careful monitoring during any surgical or invasive procedures. There is no established curative treatment. Given the severity of the bleeding phenotype, early recognition and genetic confirmation are critical for appropriate clinical management and genetic counseling of affected families.

Common questions about Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation